HHS Public Access Author manuscript Bone Marrow Transplant. Author manuscript; available in PMC 2015 July 01.

Similar documents
Biol Blood Marrow Transplant 19 (2013) 156e160

Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT

Haplo vs Cord vs URD Debate

Cover Page. The handle holds various files of this Leiden University dissertation.

Pre-Engraftment Syndrome after Double-Unit Cord Blood Transplantation: A Distinct Syndrome not Associated with Acute Graft-Versus-Host Disease

Dr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION

Histocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director

CD34+ Cells: A Comparison of Stem and Progenitor Cells in Cord Blood, Peripheral Blood, and the Bone Marrow

Reduced-intensity Conditioning Transplantation

An Introduction to Bone Marrow Transplant

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

CHAPTER 3 LABORATORY PROCEDURES

ASBMT and Marrow Transplantation

Umbilical Cord Blood Transplantation

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials

UMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Revista Cubana de Hematología, Inmunología y Hemoterapia. 2017; 36 (Suplemento).

Transplant Booklet D Page 1

Samples Available for Recipient Only. Samples Available for Recipient and Donor

The question is not whether or not to deplete T-cells, but how to deplete which T-cells

Samples Available for Recipient and Donor

Samples Available for Recipient Only. Samples Available for Recipient and Donor

Corporate Medical Policy

Donatore HLA identico di anni o MUD giovane?

SECOND ANNUAL INTERNATIONAL UMBILICAL CORD BLOOD SYMPOSIUM

Telephone: ; Fax: ; E mail:

Hematologic Safety Profile of Linezolid in the Early Periengraftment Period after Allogeneic Stem Cell Transplantation

Corporate Medical Policy

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt

Placental and Umbilical Cord Blood as a Source of Stem Cells

Is in vitro T-cell depletion necessary for Haploidentical TransplantationTitle of Presentation. Disclosure of Interest: Nothing to Disclose

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

Rapid and Robust CD4+ and CD8+ T-, NK-, BTitel and Monocyte Cell Reconstitution after Nicotinamide-Expanded Cord Blood (NiCord) Transplantation

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE

What s a Transplant? What s not?

Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched. unrelated donors

The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.

Rob Wynn RMCH & University of Manchester, UK. HCT in Children

Clinical Use of Umbilical Cord Blood Hematopoietic Stem Cells

Protocol. Hematopoietic Stem-Cell Transplantation for Primary Amyloidosis

Bases for Immunotherapy in Multiple Myeloma

Haploidentical Transplantation today: and the alternatives

Medical Benefit Effective Date: 07/01/12 Next Review Date: 03/13 Preauthorization* Yes Review Dates: 04/07, 05/08, 03/10, 03/11, 03/12

National Marrow Donor Program HLA-Matching Guidelines for Unrelated Marrow Transplants

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1

Shiv Pillai Ragon Institute, Massachusetts General Hospital Harvard Medical School

Corporate Medical Policy

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Shall young patients with severe aplastic anemia without donors receive BMT from alternative source of HCT? Elias Hallack Atta, MD, PhD

Transplantation Immunology

Transplantation Immunology

Bone Marrow Transplantation and the Potential Role of Iomab-B

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)

Intraarterial catheter guided steroid administration in treatment of steroid refractory gastrointestinal GVHD after HSCT

Immune Reconstitution Following Hematopoietic Cell Transplant

Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant

Introduction to Hematopoietic Stem Cell Transplantation

Antigen Presentation to T lymphocytes

T cell manipulation of the graft: Yes

Dr.PSRK.Sastry MD, ECMO

Indian Journal of Nephrology Indian J Nephrol 2001;11: 88-97

Allele and Haplotype Frequencies of Human Leukocyte Antigen-A, -B, -C, -DRB1, and -DQB1 From Sequence- Based DNA Typing Data in Koreans

Medical Policy. MP Placental and Umbilical Cord Blood as a Source of Stem Cells

Trapianto allogenico

Introduction 6/7/2013. Umbilical Cord Blood Transplantation: Research and Clinical Applications

Xiang-Yu Zhao, Xiao-Jun Huang, Kai-Yan Liu, Lan-Ping Xu, Dai-Hong Liu

IN UTERO HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CANINES: THE GESTATIONAL WINDOW OF OPPORTUNITY TO MAXIMIZE ENGRAFTMENT

Manipulation of T Cells in the Thnsplant Inoculum

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale

CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus

Natural Killer Cells: Development, Diversity, and Applications to Human Disease Dr. Michael A. Caligiuri

Transplantation. Immunology Unit College of Medicine King Saud University

HHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2015 September 01.

Cord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014

Cover Page. The handle holds various files of this Leiden University dissertation.

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant

Hematopoietic Stem Cells, Stem Cell Processing, and Transplantation

Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection

21/05/2018. Continuing Education. Presentation Recording. learn.immucor.com

Cancer Biology: Infectious Tumour Cells

Virological Surveillance in Paediatric HSCT Recipients

What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016

Sylwia Mizia, 1 Dorota Dera-Joachimiak, 1 Malgorzata Polak, 1 Katarzyna Koscinska, 1 Mariola Sedzimirska, 1 and Andrzej Lange 1, 2. 1.

KEY WORDS: Nonmyeloablative, Umbilical cord blood, Lymphoid malignancies

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK

Form 2033 R3.0: Wiskott-Aldrich Syndrome Pre-HSCT Data

A different view on immunity Dempsey, Claire; Jones, Nicholas

Original article. Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, 2

Impact of Cytomegalovirus (CMV) Reactivation after Umbilical Cord Blood Transplantation

Stem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT

TRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard

Corporate Medical Policy

Sickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD?

General Terms: Appendix B. National Marrow Donor Program and The Medical College of Wisconsin

Chimerix, Inc., Durham, NC; 5 Duke University Medical Center, Durham, NC

NK-KIR Gene Repertoire and Outcome of Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation from Unrelated

Transcription:

KIR and HLA genotypes have no identifiable role in single unit dominance following double unit umbilical cord blood transplantation Nidale Tarek 1,6, Meighan M. Gallagher 2,7, Joanne F. Chou 3, Marissa N. Lubin 4, Glenn Heller 3, Juliet N. Barker 4,5, and Katharine C. Hsu 4,5 1 Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 2 Immunology Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 3 Department of Epidemiology-Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY HHS Public Access Author manuscript Published in final edited form as: Bone Marrow Transplant. 2015 January ; 50(1): 150 152. doi:10.1038/bmt.2014.218. 4 Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 5 Weill Medical College of Cornell University, New York, NY Umbilical cord blood (CB) is widely used as an alternative hematopoietic stem cell source. The use of double unit CB grafts is a common strategy to augment graft cell dose and successfully leads to engraftment by a single unit. 1, 2 Current evidence suggests unit dominance is T-cell mediated; 3-5 a role for natural killer (NK) cells, however, is not excluded. NK cells mediate murine bone marrow allograft rejection and are the first lymphocytes to reconstitute following CB transplantation (CBT). 6, 7 In addition, CB NK cells are of a mature phenotype and have high cytotoxic and proliferative capacity. 6, 8, 9 We, therefore, tested the hypothesis that unit dominance after double unit CBT results from an immune interaction mediated by NK cells between the two CB units or between the recipient and the infused units. This is a retrospective analysis of 83 recipients of double unit CBT treated at Memorial Sloan-Kettering Cancer Center (MSKCC) between October 2005 and July 2010 for hematological malignancies [46 (55.4%) acute leukemia, 32 (38.5%) lymphoma and 5 (6%) other]. Sixty-six (80%) patients received a myeloablative conditioning regimen. All patients received immunosuppression with a calcineurin-inhibitor and mycophenolate mofetil. The median age of patients was 35.6 years (0.9-64.6). Informed consent for specimen collection was obtained from the patients or legal guardians in accordance with MSKCC review board guidelines. CB unit dominance was determined by molecular testing for donor chimerism Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms Katharine C. Hsu, MD, PhD, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, Tel: 646-888-2667 Fax: 646-422-0298, hsuk@mskcc.org. 6 Current address: Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX 7 Current address: Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY Conflict-of-interest disclosure: The authors declare no relevant financial interests.

Tarek et al. Page 2 from bone marrow and/or peripheral blood samples obtained at serial time-points starting from day+21 through 1 year following CBT. Unit dominance was established for all patients by day+100. Killer cell immunoglobulin-like receptors (KIR) genotyping was performed on genomic DNA 10 extracted from peripheral blood mononuclear cells or CB mononuclear cells using the QIAamp DNA Blood Minikit (Qiagen, Valencia, CA). HLA allele identification services were provided by the American Red Cross (Philadelphia, PA). The frequency distributions of KIR haplotypes and activating KIR were calculated and a chi-square test was used to determine whether these distributions differed between dominant and non-dominant units. The frequency distributions for the dominant and non-dominant units were calculated and a chi-square test was used to test whether these distributions differed in unit-unit interaction and unit-recipient interaction. The statistical package SAS (9.2) was used to generate the test statistics. KIR genotypes and HLA class I determinants of the infused CB units and the recipients are summarized in Table 1. KIR genotyping was available on 72 of the 83 CBT recipients. Results are summarized in Table 2. We compared the frequency distribution of AA and BX haplotypes within CB units. We investigated whether a CB unit exhibiting a B haplotype has more chances of dominance and investigated the impact of centromeric and telomeric B motifs in single unit dominance. CB units with A and B haplotypes showed the same rate of dominance and CB units with specific telomeric or centromeric haplotype B motifs did not show a dominance advantage. We then analyzed the frequency distribution of each activating KIR in both units. CB units possessing any one of the activating KIR did not show a higher chance of dominance. In addition, units lacking all activating KIR were not less likely to dominate. Of the activating KIR, only KIR2DS1 has class I specificity; we could not demonstrate that KIR2DS1 positive units with an HLA-C1 background were more likely to dominate if the second unit possessed HLA-C2. According to the inhibitory KIR genotype and the presence or absence of HLA class I ligands in the CB units and the recipients, different KIR and HLA interactions predictive of a missing ligand or missing self effect were evaluated. To determine the role of HLA and KIR genotypes in unit-unit interaction and single unit dominance, we investigated the hypothesis that a CB unit fails to dominate if it lacks HLA class I ligand for an individual inhibitory KIR present in the second unit (missing ligand) or if it lacks HLA class I determinants present in the second unit (missing self). We divided the CB unit pairs into 4 categories depending if none, one, or both units are missing HLA KIR ligands or selfantigens for the other unit's inhibitory KIR.KIR-HLA interactions predictive of NK alloreactivity between CB units in a unidirectional manner did not predict unit dominance. To determine the role of HLA and KIR genotypes in unit-recipient interaction and single unit dominance we investigated two different hypotheses: 1) a CB unit is more likely to dominate if the recipient lacks HLA class I ligand for specific inhibitory KIR present in the unit (missing ligand)or lacks HLA class I determinants present in the unit (missing self); or 2) a CB unit is less likely to dominate if it lacks HLA class I ligand for specific inhibitory KIR present in the recipient (missing ligand)or lacks HLA class I determinants present in the recipient (missing self). The CB unit pairs were divided in different categories depending if the recipient lacked HLA ligands or self-antigens for neither, one, or both units' inhibitory

Tarek et al. Page 3 Acknowledgments References KIR; or if neither, one or both units lacked HLA ligand or self-antigens for the recipient's inhibitory KIR. A chi-square test for equal distribution demonstrated that CB units did not have a higher likelihood of dominance if the patient was missing ligand or lacked class I determinants present in either unit. Similarly, CB units missing KIR ligand or lacking class I determinants present in the recipient did not have a lower rate of dominance. In this cohort of 83 double unit CBT recipients, we failed to find an association between KIR and HLA genotypes with unit dominance. However, our small sample size and the limited number of CB pairs with unilateral NK alloreactivity may have precluded us in finding an association if one exists. The role of KIR and HLA genotypes in unit dominance still cannot be excluded and larger studies investigating this question are warranted. We would like to acknowledge the adult and pediatric bone marrow transplantation teams at Memorial Sloan- Kettering Cancer Center, Christina Castellan for her help in the collection of clinical data, Anne Marie Gonzales and Rebecca Hawke for verifying the clinical and HLA data, and Nabila Noor for her assistance with KIR genotyping. Grant support: This study was supported in part by the National Institute of Health (P01-CA023766, R01- HL088134, and U01 AI069197) 1. Barker JN, Weisdorf DJ, DeFor TE, Blazar BR, McGlave PB, Miller JS, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood. 2005; 105(3):1343 7. [PubMed: 15466923] 2. Kang HJ, Yoo KH, Lee JW, Kim H, Lee SH, Sung KW, et al. Double umbilical cord blood transplantation for children and adolescents. Ann Hematol. 89(10):1035 44. [PubMed: 20508938] 3. Eldjerou LK, Chaudhury S, Baisre-de Leon A, He M, Arcila ME, Heller G, et al. An in vivo model of double-unit cord blood transplantation that correlates with clinical engraftment. Blood. 2010; 116(19):3999 4006. [PubMed: 20587781] 4. Avery S, Shi W, Lubin M, Gonzales AM, Heller G, Castro-Malaspina H, et al. Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts. Blood. 2011; 117(12):3277 85. quiz 3478. [PubMed: 21149633] 5. Gutman JA, Turtle CJ, Manley TJ, Heimfeld S, Bernstein ID, Riddell SR, et al. Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T- cell response against the nonengrafted unit. Blood. 115(4):757 65. [PubMed: 19822900] 6. Beziat V, Nguyen S, Lapusan S, Hervier B, Dhedin N, Bories D, et al. Fully functional NK cells after unrelated cord blood transplantation. Leukemia. 2009; 23(4):721 8. [PubMed: 19151772] 7. Murphy WJ, Kumar V, Bennett M. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med. 1987; 165(4):1212 7. [PubMed: 3549961] 8. Han P, Hodge G, Story C, Xu X. Phenotypic analysis of functional T-lymphocyte subtypes and natural killer cells in human cord blood: relevance to umbilical cord blood transplantation. Br J Haematol. 1995; 89(4):733 40. [PubMed: 7772509] 9. Woll PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol. 2005; 175(8):5095 103. [PubMed: 16210613] 10. Hsu KC, Liu XR, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. Killer Ig-like receptor haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol. 2002; 169(9):5118 29. [PubMed: 12391228]

Tarek et al. Page 4 Table 1 KIR and HLA genotypes for double unit CBT recipients and CB units Recipients Dominant CB units Non-dominant CB units KIR Genotype Total n=72 Total n=83 Total n=83 Activating KIR 2DS1 Present 29 (40%) 29 (35%) 25 (30%) Absent 43 (60%) 54 (65%) 58 (70%) 2DS2 Present 38 (53%) 42 (51%) 37 (45%) Absent 34 (47%) 41 (49%) 46 (55%) 2DS3 Present 22 (31%) 25 (30%) 24 (29%) Absent 50 (69%) 58 (70%) 59 (71%) 2DS4 Present 60 (83%) 55 (66%) 45 (54%) Absent 12 (17%) 28 (34%) 38 (46%) 2DS5 Present 23 (32%) 32 (38.5%) 30 (36%) Absent 49 (68%) 51 (61.5%) 53 (64%) 3DS1 Present 29 (40%) 30 (36%) 41 (49%) Absent 43 (60%) 53 (64%) 42 (51%) KIR 1D Present 33 (46%) 44 (53%) 44 (53%) Absent 39 (54%) 39 (47%) 39 (47%) Inhibitory KIR 2DL1 Present 67 (93%) 53 (64%) 47 (57%) Absent 5 (7%) 30 (36%) 36 (43%) 2DL2 Present 37 (51%) 44 (53%) 36 (43%) Absent 35 (49%) 39 (47%) 47 (57%) 2DL3 Present 61 (85%) 69 (83%) 75 (90%) Absent 11 (15%) 14 (17%) 8 (10%) 3DL1 Present 67 (93%) 79 (95%) 72 (87%) Absent 5 (7%) 4 (5%) 11 (13%) Haplotypes

Tarek et al. Page 5 Recipients Dominant CB units Non-dominant CB units AA 22 (31%) 16 (19.3%) 22 (26.5%) BX 50 (69%) 67 (80.7%) 61 (73.5%) HLA KIR ligands Total n=83 Total n=83 Total n=83 HLA-B Bw4/Bw4 16 (19%) 16 (19%) 16 (19%) Bw4/Bw6 47 (57%) 34 (41%) 41 (50%) Bw6/Bw6 20 (24%) 33 (40%) 26 (31%) HLA-C C1/C1 27 (32%) 24 (29%) 27 (33%) C1/C2 38 (46%) 34 (41%) 39 (47%) C2/C2 18 (22%) 25 (30%) 17 (20%)

Tarek et al. Page 6 Table 2 KIR and HLA genotypes do not predict unit dominance following double unit CBT KIR haplotype B and the presence of one or more activating KIR were not associated with CB unit dominance. KIR/HLA genotypes in unit-unit and unit-recipient interactions were not associated with CB unit dominance. Centromeric KIR KIR HAPLOTYPES Dominant CB units Non-dominant CB units P value Total n=83 n(%) Total n=83 n (%) AA 38 (45.7%) 41(49.4%) 0.64 AB+BB 45 (54.3%) 42 (50.6%) Activating KIR None 9 (10.8%) 8 (9.6%) 0.80 >1 74 (89.2%) 75 (90.4%) Unit-Unit interaction KIR and HLA Genotypes Observed N P value Non-dominant unit missing KIR ligand 13 0.85 Dominant unit missing KIR ligand 15 Both units missing KIR ligand (n=35) Neither unit missing KIR ligand (n=20) Non-dominant unit missing self 6 0.23 Dominant unit missing self 12 Both units missing self (n=24) Neither unit missing self (n=41) Unit-Recipient interaction Recipient missing ligand for dominant unit inhibitory KIR 5 0.45 Recipient missing ligand for non-dominant unit inhibitory KIR 2 Recipient missing ligand for both units (n=43) Recipient missing ligand for neither units (n=33) Recipient missing self for dominant unit inhibitory KIR 9 0.8 Recipient missing self for non-dominant unit inhibitory KIR 7 Recipient missing self for both units (n=9) Recipient missing self for neither units (n=58) Non-dominant unit missing ligand for recipient inhibitory KIR 11 0.83 Dominant unit missing ligand for recipient inhibitory KIR 13 Both units missing KIR ligand (n=33) Neither unit missing KIR ligand (n=15)

Tarek et al. Page 7 KIR HAPLOTYPES Dominant CB units Non-dominant CB units P value Total n=83 n(%) Total n=83 n (%) Non-dominant unit missing self for recipient inhibitory KIR 8 0.81 Dominant unit missing self for recipient inhibitory KIR 10 Both units missing self (n=11) Neither unit missing self (n=43)